Healthcare as an asset class is unique – it offers defensive properties, but it’s also a secular grower. Following multiple years of underperformance, healthcare relative valuations are at a level we’ve only seen twice in the last 20 years. Now, we’re seeing the greatest long-term opportunities in the biotechnology sector despite negative sentiment towards the industry. While there’s clearly going to be volatility and some uncertainty related to the size of budget cuts, the impact of tariffs, and potential regulatory changes, we simply do not see significant existential risk to the sector.
Watch our analysis on how harnessing innovation in healthcare might be the right choice for you: